GlassScriptPhysician profile
Erin M Walsh
NPI 1346810272
$9,251.30
in general payments reported to CMS, 2019-2025
26 companies · $2,932 in 2025
The $2,932 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $1,827 · 2023: $2,433 · 2024: $1,780 · 2025: $2,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,813 · Education: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,813.28 |
| Education | $331.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,665.01 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,111.85 | 2021-2025 | Ingrezza |
| Abbvie INC. | $1,057.91 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $714.51 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $660.69 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $637.82 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $534.69 | 2022-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Corium, LLC | $497.10 | 2022-2024 | Azstarys |
| Lundbeck LLC | $490.75 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $377.74 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $348.91 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $151.34 | 2022-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $148.40 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Almatica Pharma LLC | $134.69 | 2024-2025 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $117.07 | 2022-2023 | Jornay Pm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $115.95 | 2021-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $102.66 | 2022-2024 | Quviviq |
| Acadia Pharmaceuticals INC | $100.67 | 2025 | Nuplazid |
| Lilly USA, LLC | $77.55 | 2022-2024 | Amyvid |
| Avanir Pharmaceuticals, INC. | $66.65 | 2022 | |
| Boston Scientific Corporation | $45.70 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.67 | 2022 | |
| Owp Pharmaceuticals, INC. | $19.61 | 2022 | |
| Noven Therapeutics, LLC | $19.47 | 2021 | |
| Neos Therapeutics, LP | $18.93 | 2024 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $13.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.